Back to all studies
RecruitingNCT05973851

The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.

This study is recruiting in the United Kingdom, in Austria, in Germany, .... It focuses on depression.

DepressionDrugFrom 18 Years to 65 Years
Need help deciding?

Ask HopeStage to review this study with me

Loading the security check...
Study ID: NCT05973851. We help you review the study, but cannot decide medical eligibility.
In plain English

Key information made simple

This study is looking at whether a digital support tool can help people with depression or Treatment Resistant Depression. Participants receive a study treatment and complete follow-up visits and assessments. Taking part may give some people access to a digital support tool, but direct benefit is not guaranteed.

What to expect

Your next step

The official record suggests in-person participation through a hospital, with sites including Medical University Innsbruck, Universitätsklinik für Psychiatrie und Psychotherapie Bielefeld, and LWL-Klinik Dortmund, Bereich Forschung & Wissenschaft in Dortmund. Participation appears to involve assessments along with scans or samples to help researchers understand patterns more clearly. The main fit is usually being able to understand the study and consent and matching the main diagnosis, while common reasons not to take part include pregnancy or breastfeeding and safety concerns that need urgent care first. This is a later-stage study, which usually means a larger group and a closer look at how well the approach holds up.

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateStarted: August 31, 2024
Recruitment status
Recruiting
Estimated enrollment
Not clearly listed
Sponsor
Dr. Inge Winter
Sponsor type
Individual investigator
Study type
Drug
Intervention type
Medication / drug
Study phase
Not clearly listed
Locations
United Kingdom, Austria, Germany, ...
Age range
From 18 Years to 65 Years
Official registry ID
NCT05973851
Official source
Official registry link

Want help reviewing this study?

Loading the security check...
Study ID: NCT05973851. We help you review the study, but cannot decide medical eligibility.
Why this study may matter

Why this study may matter

This study may matter because it adds public evidence around depression. HopeStage presents it as a starting point for understanding the study, checking the official source, and preparing questions with a care team.

In practice

For you

Taking part may give access to a new approach being evaluated.

It requires regular visits and structured follow-up.

Requires travel, with in-person participation in Austria.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is this study trying to understand?

This study is exploring digital app or tool for people with depression. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.

Does this study involve a medication?

This appears to be a medication / drug study. The phase is not clearly listed in the public registry. Phase is mostly relevant for medication studies and some device studies. For this study, it may be more useful to look at what is required, the duration, visits, and eligibility criteria.

Who might this study be for?

This study may concern people with depression; age range: From 18 Years to 65 Years. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.

What would I likely need to do?

You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

What side effects, interactions, or treatment changes should I check?

If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.

Will I need to travel or attend in-person visits?

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

Who is behind this study?

This study is sponsored by Dr. Inge Winter, which appears to be an individual investigator. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

Can I still join this study?

The registry indicates that this study is currently recruiting. This does not mean you are eligible: the study team must confirm the criteria, available locations, and next steps.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me
The Effect of a Six Week Intensified Pharmacological Treatment for. — Depression Clinical Trial | HopeStage